R&D Systems代理4055-CR-050 Recombinant Human Cyr61/CCN1 Fc Chimera Protein, CF (50 UG)

2025-06-28

货号:4055-CR-050

品牌:R&D Systems

规格:50ug

目录价:¥4350.00

市场价格:¥3480.00

会员价格:¥3480.00

  • 到货时间:3~4周

    金山科研平台,产品价格货期咨询微信:jinshanbio Source:Chinese Hamster Ovary cell line, CHO-derived Accession #:O00622 N-terminal Sequence Analysis:Ala22 Structure:Disulfide-linked homodimer Purity:>90%, by SDS-PAGE under reducing conditions and visualized by silver stain. Endotoxin Level: Predicted Molecular Mass:66.3 kDa SDS-PAGE:70-75 kDa, reducing conditions Activity:Measured by its ability to mediate Balb/3T3 mouse embryonic fibroblast cell adhesion. Ball, D.K. etal. (2003) Reproduction 125:271. Recombinant Human Cyr61/CCN1 Fc Chimera immobilized at 1.5 µg/mL, 100µL/well, will mediate > 25% BALB/3T3 cell adhesion (3 x 104 cell/well added). Formulation:Lyophilized from a 0.2 µm filtered solution in PBS and NaCl.See Certificate of Analysis for details. Molecule Information: Cyr61/CCN1 Long Name: Cysteine-Rich, Angiogenic Inducer 61 Aliases: CCN1; GIG1; IGFBP-10 Entrez Gene IDs: 3491 (Human); 16007 (Mouse); 83476 (Rat) Background: Cyr61

    View Cyr61 IHC images. Cyr61, also known as IGFBP-10 and CCN1, is a 50 kDa matricellular glycoprotein that regulates the growth and adhesion of vascular endothelial cells, fibroblasts, and monocytes. Cyr61 induces VEGF upregulation, angiogenesis, and tumorigenesis through interactions with integrins alpha V beta 3, alpha V beta 5, alpha M beta 2, and alpha 6 beta 1. Cyr61 is cleaved by plasmin within its VWF domain which generates an N-terminal fragment that is not associated with the matrix but retains the ability to induce endothelial cell migration.

    © 金山科研平台是专业的授权总代理区域代理经销平台。
    © 如需询价,请加客服QQ:1749072012 、客服微信:jinshanbio,或发送邮件到1749072012@qq.com
    © 平台为生命科学研究相关领域提供一站式耗材试剂仪器解决方案和采购服务,数据资源基于CC协议。
    © 本文地址:https://16ao.com/thread-135217.htm
    © R&D Systems代理4055-CR-050 Recombinant Human Cyr61/CCN1 Fc Chimera Protein, CF (50 UG),产品报价联系微信jinshanbio
  • 产品询价需求提交
    产品询价请加微信:jinshanbio
    返回